FluoretiQ Limited

📢 We're thrilled to join the Veterinary Health Innovation Engine incubator and look forward to working closely with the team at Zoetis and SETsquared Surrey, as well as the mentors and advisors. Josephine Dorh Neciah Dorh Bill Pelling Ben Carter Animal Health Angels Anna-Lisa Wesley Chris Kingdon Ben Cooper Dr. Tom Ashfield Kasra Saeb-Parsy Matthew Konneh, PhD MBA Pete Corish Annie Brooking

📢 It's World AMR Awareness Week! Thanks to Innovate UK for highlighting our contribution to the global response to AMR and Natalie Collard for the ongoing support. Please do check out the other highlights being shared this week by Global Leaders Group on AMR, Antibiotic Research UK, British Society for Antimicrobial Chemotherapy (BSAC), AMR Action Fund, INCATE, Pan American Health Organization and many others. #WAAW #AMRdiagnostics Neciah Dorh Josephine Dorh Martin Cryan Ben Cooper Ben Carter Bill Pelling Dr. Tom Ashfield Anna-Lisa Wesley Chris Kingdon Matthew Konneh, PhD MBA Pete Corish Annie Brooking Kasra Saeb-Parsy Vicki Lamch, FCCA

📢 We're thrilled and humbled to be named among Sifted's list of 16 Bristol-based startups to watch. Great to see fellow Future Space - Bristol residents and our fellow QTEC alumni QLM Technology Ltd recognised. Read more: https://lnkd.in/eK79tRRh Neciah Dorh Bill Pelling Ben Carter Ben CooperJosephine Dorh Martin Cryan Anna-Lisa Wesley Chris Kingdon Matthew Konneh, PhD MBA Dr. Tom Ashfield Pete Corish Annie Brooking Kasra Saeb-Parsy

We've been busy building and are happy to share more positive news on the team front. This morning, we announce formation of our Commercial Advisory Board. Anna-Lisa Wesley, Pete Corish, Chris Kingdon, Dr. Tom Ashfield, Paul Hedgeland and Matthew Konneh, PhD MBA We've carefully curated an impressive group of advisors, chaired by Anna-Lisa Wesley who have vast commercial expertise across our target markets and share our passion for antibiotic stewardship: right drug 💊 , for the right bug at the right time ⏲ Welcoming his new advisory board, CEO, Dr. Neciah Dorh said “ I am really excited and privileged to have the advice and guidance of such an eminent group of advisors and look forward to launching our first product and taking FluoretiQ to its next level of growth and success” You can read the full press release here: https://lnkd.in/e6asDJ-G Follow us on LinkedIn to stay updated on everything FluoretiQ Deepbridge Capital Kasra Saeb-Parsy Annie Brooking Josephine Dorh Martin Cryan University of Bristol Future Space - Bristol Bristol Private Equity Club Bill Pelling Ben Cooper

We are thrilled to announce the appointment of Bill Pelling as Chair! Bill is a serial entrepreneur and exited founder.  He holds an MSc in medical microbiology and brings a wealth of international experience from his time with Unipath (now Fisher Scientific), bioMerieux, and Bracco. A statement from Neciah Dorh Dorh, CEO “We're excited to have Bill join our board. He has an exceptional combination of deep scientific expertise and extensive commercial experience within our target markets which makes him a great fit for our board”   Speaking about his new appointment Bill Pelling, Chairman “I think FluoretiQ has developed game-changing AMR diagnostic technologies with the potential for vast, global impact across several, urgent unmet needs, and I plan to leverage my experience in the IVD and veterinary sectors to accelerate the company’s path to realising these opportunities”   You can read the full press release here: https://lnkd.in/eP8kKS95 Follow us on Linkedin to stay updated on everything FluoretiQ Deepbridge Capital Bristol Private Equity Club Josephine Dorh Martin Cryan Ben Cooper Ben Carter University of Bristol Future Space - Bristol Kasra Saeb-Parsy Annie Brooking Tom El-Shawk Thanh Quan-Nicholls

Time for a big announcement! We have been awarded a £1.4 million Invention for Innovation (i4i) grant from the NIHR (National Institute for Health and Care Research)! The NIHR i4i Programme is a translational research funding scheme aimed at medical devices, in vitro diagnostic devices and digital health technologies addressing an existing or emerging health or social care need. Healthcare professionals regularly prescribe antibiotics to patients with urinary tract infection (UTI) symptoms without confirmation that an infection is present, nor whether it is resistant to the antibiotics prescribed. Over this 3 year project, we will work as the Industry development partner alongside University of Bristol, University of Oxford, Sheffield Hallam University and Sheffield Teaching Hospitals NHS Foundation Trust to develop a point of care test for antibiotic resistant urinary tract infections. Founder and CTO of FluoretiQ Limited, Josephine Dorh, says that development of a sub 1-hour test in the community would have major benefits for antibiotic prescribing: "We think that SCFI is a game changer for effective antimicrobial stewardship. FluoretiQ looks forward to an exciting collaboration to deliver a fast and accurate point of care product to improve UTI patient outcomes.'' You can read the full UoB press release here: https://lnkd.in/ea6vnPH2 Follow us on Linkedin to stay updated on everything FluoretiQ Neciah Dorh, James Preece, Helen Bolton, Kabir Bonney-Bhandal, Chrisann Haughton, Future Space - Bristol, Michael O'Donnell, Kasra Saeb-Parsy, Tom El-Shawk, Matthew Avison, Annie Brooking, Bill Pelling, North Bristol NHS Trust, Thanh Quan-Nicholls

Today we are pleased to announce that the European patent for SCFI has officially been granted! SCFI (Sub-Cellular Fluctuation Imaging) is a groundbreaking antibiotic susceptibility testing platform, invented by a team of researchers at University of Bristol, led by Dr. Massimo Antognozzi and under exclusive licence to FluoretiQ. SCFI is an optical system that uses machine learning to analyse nanoscale movement in bacterial cells. Within just 30 minutes of treatment with antibiotics, it can determine whether the cells are alive, dead or dying to determine which antibiotics will be the most effective. Founder and CTO of FluoretiQ, Josephine Dorh, says the company’s new technology can have immediate impact for several challenges facing the healthcare industry. “SCFI is truly a game changer for enabling accurate and timely antibiotic use at the point of care. We look forward to delivering a family of life-saving products from the SCFI platform.” The next stage for FluoretiQ is to continue the development of a point-of-care system – this would be one of the world’s fastest and most accurate phenotypic antibiotic susceptibility tests. We are grateful to Stu Latham and the team at Withers & Rogers for their valuable input and support through the process. Follow us on Linkedin to stay updated on everything FluoretiQ Limited Thanh Quan-Nicholls, Future Space - Bristol, Deepbridge Capital, University of Bristol, Neciah Dorh, James Preece, Rosalind Darby, Bristol Private Equity Club, OXFORD INVESTMENT OPPORTUNITY NETWORK LIMITED, massimo antognozzi

We’re very excited to announce we’ve been awarded a Scale-up For Growth (S4G) programme grant by University of the West of England. The aim of the Scale Up 4 Growth (S4G) programme is to accelerate growth in small to medium sized enterprises (SMEs).  The grant funding scheme is aimed at ambitious SMEs who can demonstrate ‘high growth potential’- the potential to generate growth by job creation or turnover in order to achieve their growth ambitions. In the PUSH project (Preparatory testing of Urine ahead of Subsequent Hospital trials), we’ll be working with the Healthtechhub and Gloucestershire Hospitals NHS Foundation Trust’ to investigate urine samples from diseased patients. The project will be led by CTO, Josephine Dorh: "We are excited to work with the team at the Healthtech Hub which will give us access to cutting edge tools and expertise. We are also grateful for the continued support from Gloucestershire Hospitals NHS Foundation Trust" Follow us on Linkedin to stay updated on everything FluoretiQ Limited Richard Luxton, Janice Kiely, Thanh Quan-Nicholls Julie Maggs, Tom El-Shawk, Future Space - Bristol

Great to hear Neciah Dorh speak at the Bristol AMR Impact event and discuss advances with new and existing collaborations. Which got us thinking, how much do you know about AMR in the South West region? University of Bristol is the UK Research and Innovation's and Newton Fund's largest recipient of AMR funded research- a whopping £44 million! There have been 206 AMR research publications published between 2016-21 with regular contributions from key opinion leaders like Darryl Hill, Matthew Avison, massimo antognozzi, James Spencer, Martin Cryan, Kristen Reyher, Alasdair MacGowan, Alastair Hay PhD projects from the GW4 Alliance that focus on #AMR research are 4x more likely to be applied for than any other subject! And Bristol is home to world-leading startups including FluoretiQ Limited, GenomeKey and FOLIUM Science who have raised 10+ million to develop leading solutions for Urinary Tract Infections, Sepsis and Animal nutrition. A big thank you to all the event organisers and look forward to see how this region continues to pioneer new ideas and innovation to tackle AMR.

“Ensuring rapid, accurate diagnostic testing is available when and where it’s needed is necessary to reducing incidence of AMR” -Hot off the press from the UK Government’s brand new 5-year AMR action plan Brilliant timing to announce that we’re part of Innovate UK’s Global Business Innovation Programme to India, chosen as one of the companies that represent the UK’s leading efforts on AMR diagnostics! India represents the forefront of AMR as a global challenge: 30-40% of patients present to clinics with multi-resistant bacterial strains, it had the second largest increase in antibiotic use between 2000-2018 and is the largest producer of generic antibiotics in the world. Very excited to learn more about the AMR challenge in India and getting to know our fellow delegates: Attomarker, BAREFOOT LIGHTNING LIMITED, CEXAL, Cytecom, Erebagen, FOLIUM Science, LightOx Ltd, Microbira Limited, Phytoceutical Ltd, Presymptom Health, Rapidx Bio, Sunny C., Dr Phil Packer, Karina Nimenko-Parkes, Andrew Shortt, TaBriX.co.uk, Ramanomics